ABSTRACT
Lu-177 prostate-specific membrane antigen (PSMA) has been increasingly used for treatment of metastatic castration-resistant prostate cancer. It is effective in pain palliation for bone metastasis and improves patient performance. Lu-177 PSMA treatment achieved a PSA decline of 50% or more in 44-60% of patient series. According to a meta-analysis, Lu-177 PSMA treatment led to longer survival and caused fewer adverse effects than third-line treatment options. In this review, we discuss several specific issues about timing, practical aspects, side effects, and response to the therapy.
References
1Heidenreich A, Bastian PJ, Bellmunt J, et al. EAU guidelines on prostate cancer. Part 1: Screening, diagnosis, and local treatment with curative intent-Update 2013. Eur Urol 2014;65:124-137.
2Zang J, Fan X, Wang H, et al. First-in-human study of 177Lu-EB-PSMA-617 in patients with metastatic castration-resistant prostate cancer. Eur J Nucl Med Mol Imaging 2018.
3von Eyben FE, Roviello G, Kiljunen T, et al. Third-line treatment and 177Lu-PSMA radioligand therapy of metastatic castration-resistant prostate cancer: a systematic review. Eur J Nucl Med Mol Imaging 2018;45:496-508.
4Emmett L, Willowson K, Violet J, Shin J, Blanksby A, Lee J. Lutetium 177 PSMA radionuclide therapy for men with prostate cancer: a review of the current literature and discussion of practical aspects of therapy. J Med Radiat Sci 2017;64:52-60.
5Lütje S, Heskamp S, Cornelissen AS, et al. PSMA Ligands for Radionuclide Imaging and Therapy of Prostate Cancer: Clinical Status. Theranostics 2015;5:1388-1401.
6Pfestroff A, Luster M, Jilg CA, et al. Current status and future perspectives of PSMA-targeted therapy in Europe: opportunity knocks. Eur J Nucl Med Mol Imaging 2015;42:1971-1975.
7Yordanova A, Eppard E, Kürpig S, et al. Theranostics in nuclear medicine practice. Onco Targets Ther 2017;10:4821-4828.
8Kabasakal L, AbuQbeitah M, Aygün A, et al. Pre-therapeutic dosimetry of normal organs and tissues of (177)Lu-PSMA-617 prostate-specific membrane antigen (PSMA) inhibitor in patients with castration-resistant prostate cancer. Eur J Nucl Med Mol Imaging 2015;42:1976-1983.
9Delker A, Fendler WP, Kratochwil C, et al. Dosimetry for (177)Lu-DKFZ-PSMA-617: a new radiopharmaceutical for the treatment of metastatic prostate cancer. Eur J Nucl Med Mol Imaging 2016;43:42-51.
10Okamoto S, Thieme A, Allmann J, et al. Radiation Dosimetry for 177Lu-PSMA I&T in Metastatic Castration-Resistant Prostate Cancer: Absorbed Dose in Normal Organs and Tumor Lesions. J Nucl Med 2017;58:445-450.
11Rahbar K, Ahmadzadehfar H, Kratochwil C, et al. German Multicenter Study Investigating 177 Lu-PSMA-617 Radioligand Therapy in Advanced Prostate Cancer Patients. J Nucl Med 2017;58:85-90.
12Ahmadzadehfar H, Zimbelmann S, Yordanova A, et al. Radioligand therapy of metastatic prostate cancer using 177Lu-PSMA-617 after radiation exposure to 223Ra-dichloride. Oncotarget 2017;8:55567-55574.
13Hofman MS, Violet J, Hicks RJ, et al. (177Lu)-PSMA-617 radionuclide treatment in patients with metastatic castration-resistant prostate cancer (LuPSMA trial): a single-centre, single-arm, phase 2 study. Lancet Oncol 2018;19:825-833.
14Derlin T, Schmuck S. (177Lu)-PSMA-617 radionuclide therapy in patients with metastatic castration-resistant prostate cancer (LuPSMA trial): a single-centre, single-arm, phase 2 study. Lancet Oncol 2018;19:825-833.
15Mhawech-Fauceglia P, Zhang S, Terracciano L, et al. Prostate-specific membrane antigen (PSMA) protein expression in normal and neoplastic tissues and its sensitivity and specificity in prostate adenocarcinoma: an immunohistochemical study using mutiple tumour tissue microarray technique. Histopathology 2007;50:472-483.
16Kulkarni HR, Singh A, Langbein T, et al. Theranostics of prostate cancer: from molecular imaging to precision molecular radiotherapy targeting the prostate specific membrane antigen. Br J Radiol 2018:20180308.
17Rahbar K, Ahmadzadehfar H, Kratochwil C, et al. German Multicenter Study Investigating 177Lu-PSMA-617 Radioligand Therapy in Advanced Prostate Cancer Patients. J Nucl Med 2017;58:85-90.
18Kabasakal L, Toklu T, Yeyin N, et al. Lu-177-PSMA-617 Prostate-Specific Membrane Antigen Inhibitor Therapy in Patients with Castration-Resistant Prostate Cancer: Stability, Bio-distribution and Dosimetry. Mol Imaging Radionucl Ther 2017;26:62-68.
19Yadav MP, Ballal S, Tripathi M, et al. 177Lu-DKFZ-PSMA-617 therapy in metastatic castration resistant prostate cancer: safety, efficacy, and quality of life assessment. Eur J Nucl Med Mol Imaging 2017;44:81-91.
20van Kalmthout LWM, Lam MGEH, de Keizer B, et al. Impact of external cooling with icepacks on 68Ga-PSMA uptake in salivary glands. EJNMMI Res 2018;8:56.
21Baum RP, Langbein T, Singh A, et al. Injection of Botulinum Toxin for Preventing Salivary Gland Toxicity after PSMA Radioligand Therapy: an Empirical Proof of a Promising Concept. Nucl Med Mol Imaging 2018;52:80-81.
22Rathke H, Giesel FL, Flechsig P, et al. Repeated 177Lu-Labeled PSMA-617 Radioligand Therapy Using Treatment Activities of Up to 9.3 GBq. J Nucl Med 2018;59:459-465.
23Demir M, Abuqbeitah M, Uslu-Beşli L, et al. Evaluation of radiation safety in (177)Lu-PSMA therapy and development of outpatient treatment protocol. J Radiol Prot 2016;36:269-278.
24Türkiye Atom Enerjisi Kurumu (TAEK). Radyonükli̇t tedavi̇si̇ gören hastalarin taburcu edi̇lmesi̇ne i̇li̇şki̇n kilavuz RSGD-KLV-009 (Rev.1). Ankara, 2018.
25Demir M, Abuqbeitah M, Uslu-Beşli L, et al. Evaluation of radiation safety in (177)Lu-PSMA therapy and development of outpatient treatment protocol. J Radiol Prot 2016;36:269-278.
26Rahbar K, Bögeman M, Yordanova A, et al. Delayed response after repeated 177Lu-PSMA-617 radioligand therapy in patients with metastatic castration resistant prostate cancer. Eur J Nucl Med Mol Imaging 2018;45:243-246.
27Scher HI, Halabi S, Tannock I, et al. Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group. J Clin Oncol 2008;26:1148-1159.
28Virgolini I, Decristoforo C, Haug A, Fanti S, Uprimny C. Current status of theranostics in prostate cancer. Eur J Nucl Med Mol Imaging 2018;45:471-495.
29Filss C, Heinzel A, Miiller B, et al. Relevant tumor sink effect in prostate cancer patients receiving 177Lu-PSMA-617 radioligand therapy. Nuklearmedizin 2018;57:19-25.
30Färkkilä N, Torvinen S, Roine RP, et al. Health-related quality of life among breast, prostate, and colorectal cancer patients with end-stage disease. Qual Life Res 2014;23:1387-1394.
31Kratochwil C, Giesel FL, Eder M, et al. (177Lu)Lutetium-labelled PSMA ligand-induced remission in a patient with metastatic prostate cancer. Eur J Nucl Med Mol Imaging 2015;42:987-988.
32Weineisen M, Schottelius M, Simecek J, et al. 68Ga- and 177Lu-Labeled PSMA I&T: Optimization of a PSMA-Targeted Theranostic Concept and First Proof-of-Concept Human Studies. J Nucl Med 2015;56:1169-1176.
33Study of 177Lu-PSMA-617 In Metastatic Castrate-Resistant Prostate Cancer (VISION). https://clinicaltrials.gov/ct2/show/NCT03511664?term=177lu&rank=9
34Ahmadzadehfar H, Schlolaut S, Fimmers R, et al. Predictors of overall survival in metastatic castration-resistant prostate cancer patients receiving (177Lu)Lu-PSMA-617 radioligand therapy. Oncotarget 2017;8:103108-103116.
35Kabasakal L, AbuQbeitah M, Aygün A, et al. Pre-therapeutic dosimetry of normal organs and tissues of (177)Lu-PSMA-617 prostate-specific membrane antigen (PSMA) inhibitor in patients with castration-resistant prostate cancer. Eur J Nucl Med Mol Imaging 2015;42:1976-1983.
